Xencor, Inc.
http://www.xencor.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xencor, Inc.
Xencor Gets CD20xCD3 Bispecific Back From J&J
Deal snapshot: J&J decided to return global rights to platotamab, a Phase II-ready CD20xCD3 bispecific antibody for hematological cancers, but remains partnered with Xencor on candidates for prostate cancer and B-cell malignancies.
Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid
Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.
Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases
Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.
Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology
Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice